Metamizole & blood thinners in cancer patients
Part of Blood & lymphatic, Brain & nervous system, Heart & circulation clinical trials.
This study is checking if metamizole (a common painkiller) changes how well the blood thinners apixaban or rivaroxaban work in cancer patients. It aims to help doctors safely use both medicines together for pain and blood clot prevention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have cancer.
- You are taking a blood thinner called apixaban (Eliquis) or rivaroxaban (Xarelto).
- You are taking metamizole (dipyrone, Optalgin) for pain, at least 1 gram three times a day (total 3 grams daily).
- Your platelet count (a measure of blood clotting cells) is at least 100,000 per microliter.
- You are generally active and able to care for yourself (mild or no disability from your cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
This trial tests an oral blood thinner (a type of drug called a direct oral anticoagulant) to see if it can reduce pain and improve quality of life in people with painful venous malformations. The drug may help by preventing abnormal blood clotting inside the malformation.
This study compares two daily pills, aspirin and rivaroxaban, to find which is better at preventing dangerous blood clots in people newly diagnosed with multiple myeloma who are at high risk. Participants will be randomly assigned to one of the two treatments.
Hear when a new Oncologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.